44.22
+0.75(+1.73%)
Currency In USD
Address
60 Leveroni Court
Novato, CA 94949
United States of America
Phone
415 483 8800
Website
Sector
Healthcare
Industry
Biotechnology
Employees
1276
First IPO Date
January 31, 2014
| Name | Title | Pay | Year Born |
| Dr. Emil D. Kakkis M.D., Ph.D. | Founder, President, Chief Executive Officer & Director | 1.46M | 1960 |
| Mr. Howard Horn | Executive Vice President of Corporate Strategy & Chief Financial Officer | 184,808 | 1978 |
| Mr. Dennis Karl Huang | Chief Technical Operations Officer and Executive Vice President of Gene Therapy Research & Development | 331,330 | 1965 |
| Mr. Thomas R. Kassberg | Chief Business Officer & Executive Vice President | 714,838 | 1960 |
| Ms. Karah Herdman Parschauer J.D. | Chief Legal Officer & Executive Vice President of Corporate Affairs | 846,744 | 1978 |
| Mr. John Richard Pinion II | Chief Quality Operations Officer & Executive Vice President of Translational Sciences | 860,053 | 1966 |
| Mr. Erik Harris M.B.A. | Executive Vice President & Chief Commercial Officer | 878,767 | 1970 |
| Mr. Ernie W. Meyer | Chief Human Resources Officer & Executive Vice President | 0 | 1965 |
| Mr. Vimal Srivastava | Senior Vice President of Business Development & Alliance Management | 0 | 1965 |
| Mr. Theodore A. Huizenga | Senior Vice President, Corporate Controller & Principal Accounting Officer | 0 | 1971 |
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc., Solid Biosciences Inc.; and Daiichi Sankyo Co., Ltd. Ultragenyx Pharmaceutical Inc. was incorporated in 2010 and is headquartered in Novato, California.